ES2130428T3 - Cristales de insulina asp-b28. - Google Patents

Cristales de insulina asp-b28.

Info

Publication number
ES2130428T3
ES2130428T3 ES94918771T ES94918771T ES2130428T3 ES 2130428 T3 ES2130428 T3 ES 2130428T3 ES 94918771 T ES94918771 T ES 94918771T ES 94918771 T ES94918771 T ES 94918771T ES 2130428 T3 ES2130428 T3 ES 2130428T3
Authority
ES
Spain
Prior art keywords
asp
insulin crystals
crystals
insulin
protamine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES94918771T
Other languages
English (en)
Inventor
Per Balschmidt
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novo Nordisk AS
Original Assignee
Novo Nordisk AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DK93727A external-priority patent/DK72793D0/da
Application filed by Novo Nordisk AS filed Critical Novo Nordisk AS
Application granted granted Critical
Publication of ES2130428T3 publication Critical patent/ES2130428T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Endocrinology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Obesity (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

LA PRESENTE INVENCION SE REFIERE A CRISTALES DE INSULINA ASP{SUP,B28} Y PROTAMINA Y PREPARACIONES FARMACEUTICAS QUE LA CONTIENEN. LOS CRISTALES Y PREPARACIONES EXHIBEN UNA ACTIVIDAD INICIADORA RAPIDA Y PROLONGADA CUANDO SE ADMINISTRAN IN VIVO.
ES94918771T 1993-06-21 1994-06-21 Cristales de insulina asp-b28. Expired - Lifetime ES2130428T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DK93727A DK72793D0 (da) 1993-06-21 1993-06-21 Nyt produkt
US08/127,672 US5547930A (en) 1993-06-21 1993-09-28 AspB28 insulin crystals

Publications (1)

Publication Number Publication Date
ES2130428T3 true ES2130428T3 (es) 1999-07-01

Family

ID=26064536

Family Applications (1)

Application Number Title Priority Date Filing Date
ES94918771T Expired - Lifetime ES2130428T3 (es) 1993-06-21 1994-06-21 Cristales de insulina asp-b28.

Country Status (10)

Country Link
EP (1) EP0705275B1 (es)
JP (1) JP2837956B2 (es)
AT (1) ATE176482T1 (es)
AU (1) AU6995794A (es)
DE (4) DE69416409T2 (es)
DK (1) DK0705275T3 (es)
ES (1) ES2130428T3 (es)
GR (1) GR3030130T3 (es)
NL (3) NL300021I2 (es)
WO (1) WO1995000550A1 (es)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK72793D0 (da) * 1993-06-21 1993-06-21 Novo Nordisk As Nyt produkt
US5474978A (en) * 1994-06-16 1995-12-12 Eli Lilly And Company Insulin analog formulations
US5461031A (en) * 1994-06-16 1995-10-24 Eli Lilly And Company Monomeric insulin analog formulations
AU711428B2 (en) * 1994-06-16 1999-10-14 Eli Lilly And Company Monomeric insulin analog formulations
GB2327424B (en) * 1994-06-16 1999-03-31 Lilly Co Eli Monomeric insulin analog formulations
US5547929A (en) * 1994-09-12 1996-08-20 Eli Lilly And Company Insulin analog formulations
CN1198643C (zh) * 1996-06-20 2005-04-27 诺沃挪第克公司 含碳水化合物的胰岛素制品
US5866538A (en) * 1996-06-20 1999-02-02 Novo Nordisk A/S Insulin preparations containing NaCl
WO1997048414A1 (en) * 1996-06-20 1997-12-24 Novo Nordisk A/S INSULIN PREPARATIONS CONTAINING NaCl
US5948751A (en) * 1996-06-20 1999-09-07 Novo Nordisk A/S X14-mannitol
BE1013507A5 (fr) * 1996-11-22 2002-03-05 Lilly Co Eli Formulations d'analogues de l'insuline.
AU6611898A (en) * 1997-03-20 1998-10-20 Novo Nordisk A/S Method for preparation of a therapeutic powder through coprecipitation of insulin and absorption enhancer
HUP0004169A3 (en) 1997-10-24 2001-06-28 Lilly Co Eli Insoluble insulin compositions and process for production thereof
CO4970787A1 (es) 1997-12-23 2000-11-07 Lilly Co Eli Composiciones insolubles de insulina y derivados de insulina que controlan la glucosa sanguinea
US20010007853A1 (en) * 1998-01-08 2001-07-12 Dimarchi Richard Dennis Method for administering monomeric insulin analogs
AU1870099A (en) * 1998-01-09 1999-07-26 Novo Nordisk A/S Stabilised insulin compositions
DE19825447A1 (de) * 1998-06-06 1999-12-09 Hoechst Marion Roussel De Gmbh Neue Insulinanaloga mit erhöhter Zinkbildung
EP2243776A1 (en) 2001-10-12 2010-10-27 High Point Pharmaceuticals, LLC Substituted piperidines and their use for the treatment of diseases related to the histamine H3 receptor
JP4629657B2 (ja) 2003-04-11 2011-02-09 ハイ・ポイント・ファーマスーティカルズ、エルエルシー １１β−ヒドロキシステロイドデヒドロゲナーゼ１型化活性化合物
CN113304250A (zh) 2003-11-20 2021-08-27 诺和诺德股份有限公司 对于生产和用于注射装置中是最佳的含有丙二醇的肽制剂
CA2614116A1 (en) 2005-07-04 2007-01-11 Novo Nordisk A/S Novel medicaments
ES2426345T3 (es) 2005-07-20 2013-10-22 Eli Lilly And Company Compuesto unidos en posición 1-amino
CA2629223C (en) 2005-11-17 2013-08-06 Eli Lilly And Company Glucagon receptor antagonists, preparation and therapeutic uses
ES2397659T3 (es) 2006-03-15 2013-03-08 Novo Nordisk A/S Mezclas de amilina e insulina
WO2007110364A1 (en) 2006-03-28 2007-10-04 High Point Pharmaceuticals, Llc Benzothiazoles having histamine h3 receptor activity
EA016415B1 (ru) 2006-04-24 2012-04-30 Эли Лилли Энд Компани Ингибиторы 11-бета-гидроксистероид-дегидрогеназы типа 1
CN102295606A (zh) 2006-05-29 2011-12-28 高点制药有限责任公司 合成3-（1，3-苯并间二氧杂环戊烯-5-基）-6-（4-环丙基哌嗪-1-基）-哒嗪的方法及其适用的中间体
EP2164466A1 (en) 2007-06-01 2010-03-24 Novo Nordisk A/S Spontaneously dispersible preconcentrates including a peptide drug in a solid or semisolid carrier
EP2514407A1 (en) 2007-06-01 2012-10-24 Novo Nordisk A/S Stable non-aqueous pharmaceutical compositions
EP3228320B1 (de) 2008-10-17 2019-12-18 Sanofi-Aventis Deutschland GmbH Kombination von einem insulin und einem glp-1-agonisten
US8927549B2 (en) 2008-11-21 2015-01-06 High Point Pharmaceuticals, Llc Adamantyl benzamide derivatives
AR080669A1 (es) 2009-11-13 2012-05-02 Sanofi Aventis Deutschland Composicion farmaceutica que comprende un agonista de glp-1, una insulina y metionina
UY33025A (es) 2009-11-13 2011-06-30 Sanofi Aventis Deustschland Gmbh Composicion farmaceutica que comprende un agonista de glp-1 metionina
MX339614B (es) 2010-08-30 2016-06-02 Sanofi - Aventis Deutschland GmbH Uso de ave0010 para la fabricacion de un medicamento para el tratamiento de la diabetes mellitus tipo 2.
WO2012104834A1 (en) 2011-02-03 2012-08-09 Pharmedica Ltd. New oral dissolving films for insulin administration, for treating diabetes
US9821032B2 (en) 2011-05-13 2017-11-21 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
RU2650616C2 (ru) 2011-08-29 2018-04-16 Санофи-Авентис Дойчланд Гмбх Фармацевтическая комбинация для применения при гликемическом контроле у пациентов с сахарным диабетом 2 типа
TWI559929B (en) 2011-09-01 2016-12-01 Sanofi Aventis Deutschland Pharmaceutical composition for use in the treatment of a neurodegenerative disease
TWI641381B (zh) * 2013-02-04 2018-11-21 法商賽諾菲公司 胰島素類似物及／或胰島素衍生物之穩定化醫藥調配物
WO2015104314A1 (en) 2014-01-09 2015-07-16 Sanofi Stabilized pharmaceutical formulations of insulin analogues and/or insulin derivatives
JP2020143105A (ja) * 2014-01-09 2020-09-10 サノフイＳａｎｏｆｉ インスリンアスパルトの安定化された医薬製剤
RU2016132386A (ru) 2014-01-09 2018-02-14 Санофи Стабилизированные фармацевтические составы без глицерина на основе инсулиновых аналогов и/или инсулиновых производных
CN114939156A (zh) * 2014-01-09 2022-08-26 赛诺菲 门冬胰岛素的稳定化药物制剂
CN107206058A (zh) 2014-12-12 2017-09-26 赛诺菲-安万特德国有限公司 甘精胰岛素/利西拉来固定比率配制剂
TWI748945B (zh) 2015-03-13 2021-12-11 德商賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患治療
TW201705975A (zh) 2015-03-18 2017-02-16 賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患之治療
WO2017163159A1 (en) * 2016-03-21 2017-09-28 Wockhardt Limited Biphasic pharmaceutical composition of insulin human

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3327709A1 (de) * 1983-07-29 1985-02-07 Hoechst Ag, 6230 Frankfurt Insulin-derivat-kristallsuspensionen, verfahren zu deren herstellung und deren verwendung
PH25772A (en) * 1985-08-30 1991-10-18 Novo Industri As Insulin analogues, process for their preparation

Also Published As

Publication number Publication date
DE122006000015I1 (de) 2006-06-29
NL300212I1 (nl) 2006-02-01
EP0705275A1 (en) 1996-04-10
DE10199011I2 (de) 2004-10-14
WO1995000550A1 (en) 1995-01-05
DK0705275T3 (da) 1999-09-20
ATE176482T1 (de) 1999-02-15
EP0705275B1 (en) 1999-02-03
JPH08511779A (ja) 1996-12-10
AU6995794A (en) 1995-01-17
JP2837956B2 (ja) 1998-12-16
DE122006000017I1 (de) 2006-06-29
DE10199011I1 (de) 2001-04-12
DE69416409T2 (de) 1999-09-16
NL300021I2 (nl) 2006-05-01
NL300021I1 (nl) 2000-12-01
NL300211I1 (nl) 2006-02-01
DE69416409D1 (de) 1999-03-18
GR3030130T3 (en) 1999-07-30

Similar Documents

Publication Publication Date Title
ES2130428T3 (es) Cristales de insulina asp-b28.
UA66417C2 (en) Recombinant adenovirus affecting canines, pharmaceutical composition
WO2000030622A3 (de) Verwendung von dialkylfumaraten zur behandlung von host-versus-graft reaktionen und von autoimmunerkrankungen
AU672018B2 (en) Looped, hairpin ribozyme
EP1820862A3 (en) Medical preparations for the treatment of alpha-galactosidase a deficiency
PH30982A (en) Optically active 5H-pyrrolo Ä3,4-bÜ pyrazine derivative, its preparation and pharmaceutical compositions containing it.
HK1026378A1 (en) Syringe serving also as an ampoule and syringe forcollecting blood.
DE3875108D1 (de) Physiologisch aktives polypeptid und pharmazeutische komposition.
HU9201254D0 (en) Rapamicine-carbamates and medical preparations containing them as active agents
DE59407457D1 (de) Blockierung der anlagerung von keimen an menschliche zellen
BG103968A (en) Pharmaceutical antiviral composition containing glycirricinic acid and at least one protein with antiviral activity
AU4959690A (en) Single use hypodermic syringe
IT1274241B (it) Complessi agente terapeutico/matrice polimerica dotati di migliorate caratteristiche di sapore e composizioni farmaceutiche che li contengono
TR199903192T2 (xx) Eritropoetin, de�i�tirilmi� hemoglobin i�eren farmasotik kombine m�stahzarlar.
FI961938A0 (fi) Uudet taksoidit, niiden valmistus ja niitä sisältävät farmaseuttiset valmisteet
DE69013557D1 (de) An Liposome gekuppelte bioaktive Verbindungen und ihre Verwendung in pharmazeutischen Zubereitungen.
HUP9802897A3 (en) Optically active pyridyl-4h-1,2,4-oxadiazine derivatives, the use thereof in the treatment of vascular diseases and pharmaceutical composition containing the compound as active ingredient
IL85651A0 (en) Optically active oxo-isoindolinyl derivatives,their preparation and pharmaceutical compositions containing them
AU1447892A (en) Pharmaceutical preparations for the therapy of tumors containing colchicine as the active principle and methods for the use of the same
WO1999003509A3 (de) Pharmazeutische mittel enthaltend perfluoralkylgruppenhaltige trijodaromaten und ihre verwendung in der tumortherapie und interventionellen radiologie
EP0418065A3 (en) Dihydrocaffeic acid derivatives, use thereof for medical treatments and pharmaceutical preparations containing same
CA2247998A1 (en) Fragments of cr1 and their use
IT9048026A0 (it) Preparato farmaceutico e/o cosmetico.
FR2657258B1 (es)
Kieffer Cosmetic surgery of the aging face: social, psychological, and ethical implications

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 705275

Country of ref document: ES

SPCF Request for supplementary protection certificate filed

Free format text: INSULIN-ASPARTATO (NOVOMIX 30 (PENFILL/NOVOLET)).

Spc suppl protection certif: C200000035

Filing date: 20001228

Free format text: INSULIN-ASPARTATO (NOVOMIX 30 (PENFILL/NOVOLET))

Spc suppl protection certif: C200000035

Filing date: 20001228

SPCG Supplementary protection certificate granted

Free format text: INSULIN-ASPARTATO (NOVOMIX 30 (PENFILL/NOVOLET))

Spc suppl protection certif: C200000035

Filing date: 20001228

Expiry date: 20150801

Effective date: 20031205